October 23, 2023
“Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a “promising new therapy”… Continue Reading…
August 12, 2022
“Shares of GlaxoSmithKline, Sanofi and Haleon all sold off sharply this week, shedding tens of billions in market value, amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac. This has been a known issue bubbling in the background for years… Continue Reading…
January 6, 2021
“Esperion (ESPR)… Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target… Continue Reading…
January 5, 2021
“Esperion (ESPR)… Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target… Continue Reading…
November 24, 2020
“Cocrystal Pharma (COCP)… Overall, 2 Buys and no Holds or Sells have been assigned in the last three months. Therefore, the analyst consensus is a Moderate Buy. At $4.75, the average price target puts the upside potential at 452%… DiaMedica… Continue Reading…
October 19, 2020
“Athira Pharma (ATHA)… Judging by the consensus breakdown, opinions are anything but mixed. With 4 Buys and no Holds or Sells assigned in the last three months, the word on the Street is that ATHA is a Strong Buy. At… Continue Reading…
Recent Comments